GSK/Adolor Entereg approvable again
This article was originally published in Pharmaceutical Approvals Monthly
GlaxoSmithKline and Adolor plan to continue development of Entereg (alvimopan) after the NDA for management of post-operative ileus was deemed "approvable" a second time, the companies said Nov. 6. FDA noted a potential increased risk of cardiovascular events and requested additional 12-month safety data from GSK's ongoing Phase III safety study (76905/014) in opioid-induced bowel dysfunction in chronic cancer pain patients, as well as a risk management plan. The first approvable letter, issued in July 2005, requested additional efficacy data in patients following bowel resection surgery (1Pharmaceutical Approvals Monthly February 2006, p. 9). The response to the first approvable letter was submitted in May 2006; a response to the second letter appears unlikely before the second quarter of 2007, when final data from the 014 study is expected...
You may also be interested in...
Astellas Pharma receives another "approvable" letter for its once-daily formulation of its immunosuppressant Prograf (tacroliumus), dashing hopes of approval before a substance patent for the twice-daily formulation expired April 8. Prograf MR is under review for prophylaxis of organ rejection in both kidney and liver transplant patients. The Japanese firm received the second approvable letter for the liver transplant indication April 30; the kidney transplant indication got its second approvable letter in March. A heart transplant indication was deemed "not approvable" in January 2007. Astellas said it is "examining the future strategy" and working closely with FDA to better understand the issues raised. More time needed for Entereg review: After a three-month delay pushed back the user fee date for GlaxoSmithKline/Adolor's Entereg (alvimopan), FDA will not meet the scheduled May 10 action date, Adolor announces. After the Gastrointestinal Drugs Advisory Committee called the risk management plan inadequate in January, the firms submitted a new program in February. Entereg, indicated for postoperative ileus, has received two "approvable" letters since the NDA submission in 2004 (1Pharmaceutical Approvals Monthly November 2006, In Brief)
GlaxoSmithKline/Adolor's postoperative ileus agent Entereg provides a statistically significant reduction in length of hospital stay, according to trial results reported by Adolor Feb. 7
The device can conduct laparoscopic hysterectomies, giving surgeons more mobility while leaving less scarring.